Events + Media

Today, we’re highlighting the groundbreaking work of TreeFrog Therapeutics, a company aimed at making stem cell-derived cell therapies more affordable and accessible to millions of patients. TreeFrog is a resident of our newest facility, LabCentral 238, with on-site capacities to kickstart collaborative cell therapy programs in regenerative medicine and immuno-oncology. We spoke with TreeFrog’s Cofounder and Chief Technology Officer, Kevin Alessandri, Ph.D., who just moved from Bordeaux to Boston, to learn more about the company’s focus and activities.

Gallery 1832 provides residents and visitors with new avenues to find inspiration in the space around them. We believe this constantly changing environment and exposure to new perspectives is beneficial to the mind. In this spirit, the gallery space is an important part of keeping life fresh for researchers and entrepreneurs.